An interventional study of FROA-BD programme in Bipolar Disorder, sponsored by Consorcio Centro de Investigación Biomédica en Red (CIBER). Active, not recruiting at 1 site in Spain. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Consorcio Centro de Investigación Biomédica en Red (CIBER) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Bipolar Disorder with a site in Spain — 7 open to participants now, 9 under way, 2 of them phase 3. Bipolar Disorder · Spain.
Among the 53 studies in Bipolar Disorder with a site in Spain, this one is the 26th largest by planned enrollment of the 36 interventional ones that give a count, is one of 2 that started in 2023, is one of 17 with no phase, and was the 42nd registered.
1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.
Browse Bipolar Disorder studies →7 of the 53 studies in Bipolar Disorder with a site in Spain are open now. Recruiting first, the newest first:
University of the Basque Country (UPV/EHU) · Sites in Spain
Ages 18–65
Dr. Inge Winter · Sites in Spain, Austria, Germany and 3 more countries
Ages 18+
Instituto de Investigacion Sanitaria La Fe · Sites in Spain
Ages 18–70
Consorcio Centro de Investigación Biomédica en Red (CIBER) · Sites in Spain
Ages 18–60
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Sites in Spain
Ages 40+ · Healthy volunteers
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 84 is above the median of 64 across 1,282 interventional studies indexed under Bipolar Disorder.
Median enrollment 132 across the 36 interventional studies, 249 across the 17 observational. Of the 38 that completed or were terminated, 7 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 53 have an industry lead sponsor. The 10 most frequent:
Consorcio Centro de Investigación Biomédica en Red (CIBER) is the lead sponsor of 18 studies on the registry; 6 are open to participants now.
Consorcio Centro de Investigación Biomédica en Red (CIBER) has 4 studies filed under Bipolar Disorder — fewer than ten, so there is no comparison to draw.
1 of the studies in Bipolar Disorder with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07921667International University of La RiojaSleep Monitoring for Early Detection of Relapse in People With Schizophrenia or Bipolar Disorder Receiving Usual Treatment | 2027-08 |
Add it to your calendar (.ics) → With an account.
Among the 53 studies in Bipolar Disorder with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Bipolar Disorder (BD) is a chronic and severe mental illness characterized by the emergence of alternating mood episodes which range from extreme depression to manic states. Beyond affective episodes, there is consensus considering that cognitive and functional impairment are also core features in a substantial proportion of patients suffering from this mental condition, being both of them responsible of a negative impact on perceived quality of life (QoL). Despite, the association between cognitive performance, clinical and functioning outcomes in patients with BD has been largely explored among adult and middle-aged patients, there is a dearth of research about aging process among older adults with bipolar disoder (OABD) as well as in the design of tailored intervention targeting older individuals. Due to the longer life expectancy and subsequent aging of the world's population, is becoming increasingly common that people presenting with chronic health condition, including BD, survives longer. Currently, it has been estimated roughly the 25% of whole BD population is over 50 years old and it is expected that this percentage will increase up to 50% by 2030. Consequently, there is an urgent need not only to explore specific implication in clinical and neurocognitive course and to investigate symptom development throughout this vital stage elder-life phase, but also to design specific interventions aimed to cope with special needs in this specific population.
Study design: This is a single-center, single-blind, randomized, controlled test-retest clinical study to evaluate the efficacy of the FROA-BD in a representative sample of patients with BD over 50 years old. This study will be carried out in the Bipolar and Depressive Disorders Unit at the Hospital Clinic of Barcelona, which takes part of the Spanish network Center for Biomedical Research in Mental Health (CIBERSAM). It will include two parallel arms (1:1) in order to assess the efficacy of a new psychological intervention as add-on therapy compared with treatment as usual to enhance functional outcome in OABD. This project has been approved by the Ethical Comittee of the Hospital Clinic of Barcelona and it will be carried up in accordance with the ethical principles of the Declaration of Helsinki and Good Clinical Practice in compliance with the data protection law in force and anonymization of the collected information.
Procedure All participants will be examined at baseline prior to inclusion in the study, using an extensive battery of questionnaires and tools aimed to assess main demographic, clinical, functioning, quality of life, well-being, and neurocognitive variables. Once the baseline assessment has been carried out, patients will be randomly allocated into the experimental group, which will receive the FROA-BD programme, or to the control group, which will be treated as usual (TAU). Four months later, when the intervention will be finished, all study participants will be assessed, especially on those areas that are supposed to be targeted by the FROA-BD programme (functional outcome as the main outcome, and neurocognitive performance, clinical symptoms, and quality of life and well-being as secondary outcomes), trying to avoid potential re-assessment learning effect by using alternative versions or tests. Finally, one year after inclusion (8 months after completion of the intervention), a complete assessment, mostly identical to which was used at baseline, will be performed (See Figure 1). In addition to the aforementioned assessment visits, all participants will also be followed up pharmacologically at the Bipolar and Depressive Disorder Unit of the Hospital Clinic of Barcelona, following the guidelines of good clinical practice. Research members involved in assessment will be blind to condition group (FROA-BD or TAU). Two clinical neuropsychologist (therapist and co-therapist) blind to baseline assessment results will conduct the FROA-BD intervention.
Data collection
Psychosocial functioning, quality of life and well-being Functional outcome will be assessed by the means of the FAST. This interviewer-administered brief scale, which comprises 24 items, was specifically designed to explore functional difficulties in psychiatric population among six specific functional domains (autonomy, occupational functioning, cognitive functioning, financial issues, interpersonal relationships and leisure time). Overall scores range from 0 to 72, being higher scores indicators of a worse functional impairment.
Quality of life and well-being will be assessed using the Spanish version of the Short Form-36 Health Survey (SF-36) and the Spanish version of the World Health Organisation-Five Well-Being Index (WHO-5), respectively. The SF-36 is self-administered questionnaire which consists of 36 questions measuring eight separate dimensions related to quality of life (physical functioning, role limitation-physical, role limitation-emotional, vitality, mental health, social functioning, pain, and general health). Higher scores indicate better quality of life. WHO-5 is a self-administered short test consisting of 5 items rated on a 6-point scale assessing how the individual has been feeling over the last two weeks. Raw score ranges from 0 to 25. The higher scores the better perceived subjective well-being. In order to obtain the feedback from the patients, we also will consider the patient's satisfaction with the intervention through a self-applied instrument measured in likert scale (from 0 to 10) where the maximum score corresponds to completely satisfied.
For the objective assessment of neurocognitive function two different batteries of tests have been selected depending of time-point assessment:
(I) Extended battery: Overall cognition will be assessed by means of the Mini Mental Status Examination (MMSE) and the Spanish version of the Screen for Cognitive Impairment in Psychiatry (SCIP-S). Both of these brief scales were specifically designed for detecting cognitive deficits, being the latter specific for psychiatric population. The SCIP-S has three alternative forms as three different time-points of the study in order to avoid learning effect bias.
The estimated Intelligence quotient (IQ) will be calculated based on the results in the Vocabulary subtest from the Wechsler Adult Intelligence Scale (WAIS-III).
The Executive functions will be measured through the computerized Wisconsin Card Sorting Test (WSCT), the Stroop Color-Word Test (SCWT); the Phonemic (F-A-S) component of the Controlled Oral Word Association Test (COWAT) the copy of the Rey Osterrieth Complex Figure (ROCF) and the Trail Making Test-Part B (TMT-B).
Attention will be assessed by using the computerized version of the Continuous Performance Test (CPT-II) and the Trail Making Test-Part A (TMT-A).
The Working memory index (WM) will be calculated based on the performance in three subtest from the WAIS-III: Arithmetic, Digits, and Letter-Number sequencing.
The assessment of the Processing speed index will comprise two subtests of the WAIS-III: the Symbol Search and the Digit-symbol Coding subtests from the WAIS-III.
Verbal Learning and Memory performance will be evaluated through the California Verbal Learning Test (CVLT).
To examine visual memory The Rey Osterrieth Complex Figure-inmediate recall (ROCF) will be administered.
Language domain will be examined by means of the Boston Naming Test (BNT) and the Categorical (Animal Naming) component of the COWAT.
Visuoespatial domain will be assessed by the Juice Line Orientation (JLO). This battery will be administered at baseline visit (V0) and 12-month follow-up visit after inclusion (V2), with the exception of vocabulary subtest which only will be applied at baseline visit since it is a measure of estimated IQ.
(II) Brief cognitive battery: In order to avoid potential learning effects, we selected a brief cognitive battery consisting of the SCIP-S form 2, the SCWT, the TMT part A and B, the CPT-II, and the semantic and phonemic components of the COWAT. This brief battery of test will be administered at post-intervention visit (V1), four months after inclusion.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Functional Remediation for Older-Age Patients With Bipolar Disorder (FROA-BD)
Behavioral: FROA-BD programme
The control group (42 patients) will not receive any type of add-on psychotherapy.
The experimental group (n=42) will receive a 4-month intervention consisting of 32 sessions of treatment.
The primary outcome measure will be changes in functioning assessed by means of the FAST from baseline to endpoint, post-intervention
The scale is interviewer-administered, designed for the assessment of psychosocial functioning. The 24 items of the scale are divided among 6 specific areas of functioning: autonomy, occupational functioning, cognitive functioning, financial issues, interpersonal relationships and leisure time. Each individual item is scored from 0 to 3. The global score (0-72) is obtained when the scores of each item are added up. The higher the score, the more serious the difficulties.
Time frame: 15 days
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2023 (actual). Primary completion is estimated for Oct 2026, 43 months after the start.
Of 361 non-industry interventional studies with no phase under Bipolar Disorder, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's planned 43 months is above that.
Counting every sponsor, half of 363 studies reached it within 37 months; a quarter within 23 and three quarters within 58.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Dec 2024 → Oct 2026 and completion Jun 2025 → Oct 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Consorcio Centro de Investigación Biomédica en Red (CIBER)